High sugar levels damage the blood vessels of the kidneys, which can cause a excessive strain on the heart and increase the risk of heart failure. Traditional treatments often have unpleasant side effects and can affect heart health. There fine renone is a medicine approved to treat patients with type 2 diabetes in advanced stages kidney failure, slowing kidney damage and reducing the risk of serious heart problems (source 1).
Environ 40 % of people with type 2 diabetes develop chronic kidney disease due to high blood sugar and the production of a hormone called aldosterone. ACE inhibitors have been used to reduce aldosterone levels, but they can increase the level of mineral potassium in the body and increase the risk of heart attack. Finerenone has shown a significant reduction in the risk of heart disease in patients, with only two percent of patients with heart disease compared to ACE inhibitors. The approval of finerenone offers a important option for delaying the progression of kidney disease in patients with type 2 diabetes and kidney disease, which account for more than a million people in England.